# Single-Dose Phase 1 Study of TAK-792

> **NCT02448719** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 72 (actual)

## Conditions studied

- Healthy Male Adults Participants

## Interventions

- **DRUG:** TAK-792 30 mg
- **DRUG:** TAK-792 30 mg placebo
- **DRUG:** TAK-792 100 mg
- **DRUG:** TAK-792 100 mg placebo
- **DRUG:** TAK-792 250 mg
- **DRUG:** TAK-792 250 mg placebo
- **DRUG:** TAK-792 500 mg
- **DRUG:** TAK-792 500 mg placebo
- **DRUG:** TAK-792 750 mg
- **DRUG:** TAK-792 750 mg placebo
- **DRUG:** TAK-792 1250 mg
- **DRUG:** TAK-792 1250 mg placebo

## Key facts

- **NCT ID:** NCT02448719
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-27
- **Primary completion:** 2016-01-28
- **Final completion:** 2016-01-28
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2019-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02448719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02448719, "Single-Dose Phase 1 Study of TAK-792". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02448719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*